DrugPatentWatch Database Preview

Drugs in Development Information for IMC-1C11

« Back to Dashboard

Summary for IMC-1C11

US Patents	10
International Patents	106
US Patent Applications	0
WIPO Patent Applications	0
Japanese Patent Applications	0
Clinical Trial Progress	Phase 3 (2015-09-01)
Vendors	0

US Patents for IMC-1C11

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
IMC-1C11		Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents	Chemaphor Inc. (Ontario, CA)
IMC-1C11		5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors	Vertex Pharmaceuticals Incorporated (Cambridge, MA)
IMC-1C11		Compositions and methods relating to anti-IGF-1 receptor antibodies	Amgen Inc. (Thousand Oaks, CA)
IMC-1C11		Compositions and methods for cancer immunotherapy	Eisai R&D Management Co., Ltd. (Bunkyo-Ku, Tokyo, JP)
IMC-1C11		Gonadotropin-releasing hormone receptor-targeting peptides and their use to treat and diagnose cancer	STC.UNM (Albuquerque, NM)
IMC-1C11		Method for cancer cell reprogramming	STC.UNM (Albuquerque, NM)
IMC-1C11		Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same	STC.UNM (Albuquerque, NM) Sandia Corporation (Albuquerque, NM)

International Patents for IMC-1C11

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
IMC-1C11	Austria	201394	2014-08-10
IMC-1C11	Australia	3160095	2014-08-10
IMC-1C11	Australia	704640	2014-08-10
IMC-1C11	Canada	2171625	2014-08-10
IMC-1C11	China	1131939	2014-08-10
IMC-1C11	Czech Republic	9601038	2014-08-10
IMC-1C11	Germany	69521020	2014-08-10